

**DOCKET NO.: AREN79.US2.PCT** 



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Graeme Semple et al.

Serial No.: 10/535,345 Group Art Unit: Not Yet Assigned

Filing Date: Herewith Examiner: Not Yet Assigned

Title: Tetrazole Derivatives and Methods of Treatment of Metabolic-Related Disorders

Thereof

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

V IA EXPRESS MAIL LABEL NO. EV552952592US Date Sent: February 15, 2006

Dear Sir:

# RESPONSE TO NOTICE OF MISSING REQUIREMENTS **UNDER 35 U.S.C. 371**

The Notification of Missing Requirements Under 35 U.S.C. 371 (copy enclosed) alleges that the application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR §§ 1.821-1.825. Applicants, however, note that there are no sequences in the application or figures meeting the definition under 37 CFR §1.821(a). Applicants have therefore not supplied a copy of a "Sequence Listing" as requested in the Notification and respectfully urge that the application is in compliance with the rules.

Respectfully submitted,


Christine A. Goddard Ph.D.

Registration No. 46,731

Date: February 15, 2006

COZEN O'CONNOR 1900 Market Street Philadelphia, PA 19103-3508 Telephone: (215) 665-2000

Facsimile: (215) 665-2013





UNITED STATES DEPARTMENT OF United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignim 22313-1450 www.uspto.gov

U.S. APPLICATION NUMBER NO

FIRST NAMED APPLICANT

ATTY. DOCKET NO.

10/535,345

Graeme Semple

79.US2.PCT

PCT/US04/35927

INTERNATIONAL APPLICATION NO.

I.A. FILING DATE

PRIORITY DATE

10/29/2004

10/31/2003

35133 COZEN O'CONNOR, P.C. 1900 MARKET STREET PHILADELPHIA, PA 19103-3508

RECEIVED COZEN IP DEPT

DEC 1 9 2005 DUE DATE 2-15-0(

MAX DATE DOCKETEDBY

**CONFIRMATION NO. 6159** 371 FORMALITIES LETTER

\*OC000000017630602\*

Date Mailed: 12/15/2005

# NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 05/18/2005
- Copy of the International Search Report filed on 05/18/2005
- Preliminary Amendments filed on 05/18/2005
- Oath or Declaration filed on 05/18/2005
- Request for Immediate Examination filed on 05/18/2005
- U.S. Basic National Fees filed on 05/18/2005
- Priority Documents filed on 05/18/2005
- Power of Attorney filed on 05/18/2005
- Specification filed on 05/18/2005
- Claims filed on 05/18/2005
- Abstracts filed on 05/18/2005

The following items MUST be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371;

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date. The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) in that it:
  - is not executed in accordance with either 37 CFR 1.66 or 37 CFR 1.68.
- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c) Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new

- \*\* matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

#### BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

### PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/535,345	PCT/US04/35927	79.US2.PCT

FORM PCT/DO/EO/905 (371 Formalities Notice)

IAPS Rec'd PCT/PTO 15 FEB 2008

PTO-1390 (Rev. 02-2005)
Ved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/UŠ) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER 79.US2.PCT						
		U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/535,345						
INTERNATIONAL APPLICATION NO. PCT/US04/35927	INTERNATIONAL FILING DATE 10/29/2004	PRIORITY DATE CLAIMED 10/31/2003						
TITLE OF INVENTION Tetrazole Derivative	s and Methods of Treatment of	<u> </u>						
Disorders Thereof  APPLICANT(S) FOR DO/EO/US Graeme Sem	nlo et al							
AFFLICANT(S) FOR BO/E0/03 GTACITIC SCITT	pie et al.							
Applicant herewith submits to the United States Desi	gnated/Elected Office (DO/EO/US) the follow	ving items and other information:						
This is a FIRST submission of items cond	cerning a submission under 35 U.S.C. 371.							
2. This is a SECOND or SUBSEQUENT sul	This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.							
3. This is an express request to begin nation (5), (6), (9) and (21) indicated below.	This is an express request to begin national examination procedures (35 U.S.C. 371 (f)). The submission must include items (5), (6), (9) and (21) indicated below.							
4. The US has been elected (Article 31).								
5. A copy of the International Application as	filed (35 U.S.C. 371(c)(2))							
a. is attached hereto (required o	a. is attached hereto (required only if not communicated by the International Bureau).							
b. has been communicated by the	he International Bureau.							
c. is not required, as the applica	c. is not required, as the application was filed in the United States Receiving Office (RO/US).							
6. An English language translation of the Int	ternational Application as filed (35 U.S.C. 37	1(c)(2)).						
a. is attached hereto.								
b. has been previously submitte	b. has been previously submitted under 35 U.S.C. 154(d)(4).							
7. Amendments to the claims of the Internat	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))							
a. are attached hereto (required	a. are attached hereto (required only if not communicated by the International Bureau).							
b. have been communicated by	b. have been communicated by the International Bureau.							
c. have not been made; howeve	c. have not been made; however, the time limit for making such amendments has NOT expired.							
d. have not been made and will	d. have not been made and will not be made.							
8. An English language translation of the an	nendments to the claims under PCT Article 1	9 (35 U.S.C. 371(c)(3)).						
9. An oath or declaration of the inventor(s) (	35 U.S.C. 371 (c)(4)). TWO EXECUTED DO	CUMENTS ARE ENCLOSED.						
10. An English language translation of the an Article 36 (35 U.S. C. 371 (c)(5)).T	nexes of the International Preliminary Exami	nation Report under PCT						
Items 11 to 20 below concern document(s) o	or information included:							
11. An Information Disclosure Statement und								
12. An assignment document for recording. A	separate cover sheet in compliance with 37	CFR 3.28 and 3.31 is included.						
13. A preliminary amendment.								
14. An Application Data Sheet under 37 CFR	1.76.							
15. A substitute specification.								
16. A power of attorney and/or change of add								
	A computer-readable form of the sequence listing in accordance with PCT Rule 13/er.2 and 37 CFR 1.821- 1.825.							
	A second copy of the published International Application under 35 U.S.C. 154(d)(4).							
19. A second copy of the English language tra	A second copy of the English language translation of the international application under 35 U.S.C.:154(d)(4).							
20. Other items or information: Response to	Notice of Missing Requirements Under 35 US	SC-371 regarding sequence requirements.						

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-1390 (Rev. 02-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	U.S. APPLICATION N 10/535,345	APPLICATION NO. (if known, see 37 CFR 1.5) INTERNATIONAL APPLICATION NO. PCT/US04/35927			ATTORNEY'S DOCKET NUMBER 79.US2.PCT				
	· · · · · · · · · · · · · · · · · · ·	The following fees are submitted:					CALCULATIONS	PTO USE ONLY	
	21. Basic national fee						\$		
						· · · · · · · · · · · · · · · · · · ·			
	22. Examination fe		4 4 6	LICOTO and all alabana	-4'-5	···			
	If International preliminar PCT Article 33(1)-(4). All other situations		\$100	<b> \$</b>					
						3200		<u> </u>	
	23. Search fee Search fee (37 CFR 1.44	45(a)(2)) has been a							
		earching Authority							
	International Search Rep All other situations			\$					
	All other situations \$500  TOTAL OF 21, 22 and 23 =						\$		
	Additional fee for spe	ecification and drawi							
	sequence listing or on the fee is \$250 for e								
	1 10 100 10 10 10 10								
	Total Sheets	Extra sheet		each additional 50 or frac and up to a whole numbe	_	RATE			
	- 100 =	/50 =				x \$250	œ.		
	Surcharge of \$130 00 fo	or furnishing the gath	or declaration	n later than 30 months fro	om the oc	diaet	<u> </u>		
	claimed priority date (37		TOT GECIATATIO		On the ear	illest	\$ 130		
	CLAIMS	NUMBER FIL	.ED	NUMBER EXTRA		RATE	\$		
	Total claims		- 20 =	· · · · · · · · · · · · · · · · · · ·		x \$50	\$		
	Independent claims		-3 =			x \$200	\$		
	MULTIPLE DEPENDENT	CLAIM(S) (if applic	able)			+ \$360	\$		
		JLATIONS =	\$ 130						
j	Applicant claims sma	all entity status. See	37 CFR 1.27	. Fees above are reduce	ed by ½.				
						SUBTOTAL=	\$ 130		
	Processing fee of \$130.0 claimed priority date (37	e earliest	\$						
	, , ,	IONAL FEE =	\$						
	Fee for recording the en by an appropriate cover	closed assignment (	(37 CFR 1.21)	(h)). The assignment mu	ist be acco		\$		
	by all appropriate cover	SHEEL (ST CFR 3.20	, 3.31). \$40.0		AL FFFS I	+ ENCLOSED =	\$ 130		
A2 /24 /2AA/	CCDCV1 00000112 E	501275 1053534					Amount to be	<del>\</del>	
02/21/2006		MIE12 10222	<del>1</del> 3				refunded: Amount to be	\$	
01 FC:1617	130.00 DA						charged	\$	
	a. A check in the	amount of \$	_ to cover the	e above fees is enclosed.					
		my Deposit Account		75 in the amount of \$ $1$	30 to cove	er the above fee	<b>95</b> .		
		•		ne any additional fees wh	ich may he	e required or cr	edit any overpayment to [	Denosit to	
	Account No. 5	<u>0-1275</u> . A duplic	ate copy of th	nis sheet is enclosed.		o required, or or	con any overpayment to t	oeposit to	
	<ul> <li>d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</li> <li>NOTE: Where an appropriate time limit under 37 CIFIR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.</li> </ul>								
:	SEND ALL CORRESPONDENCE TO:								
	EV552952592US  Christine A. Goddard, Ph.D.								
	Date Sent: February 15, 2006  Registration No. 46,731								